Application in Women: to stimulate the growth of one dominant follicle in women, two different injection schemes are used.
The first scheme: a daily dose of 75 ME in the first 7 days of the cycle in menstruating women. Injections continue until an adequate response can be judged, which can be judged by the daily analysis of the concentration of estrogens in the blood and the determination of the size of the follicles by ultrasound (ultrasound). Maturation of follicles occurs usually during the treatment cycle lasting 7-12 days. In the absence of ovarian response to administration, the daily dose of the drug can be gradually increased to 150 ME.
Second scheme: an introduction every other day for 1 week. The initial dose is 225-375 IU / day. If adequate stimulation is not achieved, the dose may be gradually increased.
After the treatment of any of the schemes and in the presence of adequate but not excessive reaction of the ovaries controlled by ultrasonic folliculometry and determination of the concentration of estradiol in the plasma 24-48 hours after the last administration of the preparation HuMoG with the aim of inducing ovulation, 5-10 thousand ME hCG, increasing the content of LH and stimulating the release of a mature egg.
In the presence of at least 3 follicles with a diameter of 16-20 mm (according to ultrasound) and an adequate ovarian response (estradiol concentration in the blood plasma of 300-400 pg / ml (1000-1300 pmol / l) per follicle with a diameter of more than 18 mm) hHG Do not inject and take measures to protect against possible pregnancy to prevent multiple pregnancies. Since each follicle with a diameter of more than 14 mm is preovulatory, the presence of several follicles with a diameter of more than 14 mm carries the risk of multiple pregnancies.
In the presence of ovulation and the absence of pregnancy, treatment can be repeated according to one of the above schemes for 2 cycles. On the day of hCG administration and the next 2-3 days, the patient is recommended to have coitus. When stimulating superovulation (when performing assisted reproductive techniques - ART), the duration of administration of the drug may be longer.
Application in men: when hypogonadotropic hypogonadism in men for the stimulation of spermatogenesis the drug is prescribed if the previous therapy with hCG caused only an androgenic reaction without signs of increased spermatogenesis.In this case, the treatment is continued by administering 2,000 IU hCG 2 times a week, along with injections of HuMoG 75 ME 3 times per week. Treatment for this regimen should be continued for at least 4 months, with ineffectiveness, treatment is continued, introducing hCG 2,000 IU twice a week and 150 IU of HuMoG 3 times a week.
The state of spermatogenesis should be assessed on a monthly basis, and if there are no positive results within the next 3 months, treatment should be discontinued.
With idiopathic normogonadotrophic oligospermia is introduced weekly 5 thousand ME hCG subcutaneously or intramuscularly, with parallel administration of 75-150 ME the drug HuMoG 3 times a week for 3 months.